DARA BioSciences, Inc. Announces Acquisition of U.S. Marketing Rights to Soltamox(TM), an FDA Approved Liquid Formulation of Tamoxifen for the Treatment of Breast Cancer

RALEIGH, N.C., Jan. 17, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it has acquired exclusive U.S. rights to sell Soltamox™, a liquid formulation of tamoxifen for the treatment of breast cancer, through the acquisition of South Carolina-based specialty pharmaceutical company, Oncogenerix, Inc. Christopher Clement, CEO of Oncogenerix and former CEO of Savient Pharmaceuticals, will join DARA as a director and as Chief Operating Officer.

MORE ON THIS TOPIC